Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Vetter

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Nephrology and Hypertension|July 10, 2002
Magnesium and the parathyroidThorsten Vetter, Martin J Lohse
Clinical Pharmacology and Therapeutics|February 28, 2019
Multistakeholder Advice at the European Medicines Agency: Is It Still Needed?Spiros Vamvakas, Jane Moseley, Thorsten Vetter
Therapeutic Innovation & Regulatory Science|March 4, 2023
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global AgeShannon Thor, Thorsten Vetter, Anabela Marcal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2014
GFR decline as an end point for clinical trials in CKD: a view from EuropePeter G M Mol, Romaldas Maciulaitis, Thorsten Vetter
Frontiers in Pharmacology|December 4, 2024
Identifying and overcoming challenges in the EMA's qualification of novel methodologies: a two-year reviewAna Drmić, Riccardo Saccà, Thorsten Vetter, et al.
Clinical Pharmacology and Therapeutics|January 18, 2025
Methodological Insights on Biomarker-Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines AgencyCynthia Huber, Joerg Zinserling, Norbert Benda, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 20, 2026
The use of albuminuria and proteinuria for regulatory clinical decision making: a perspective from European regulatorsFrank Holtkamp, Hrefna Gudmundsdottir, Karin Janssen van Doorn, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2019
Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European RegulatorsFrank Holtkamp, Hrefna Gudmundsdottir, Romaldas Maciulaitis, et al.
Frontiers in Medicine|May 13, 2022
Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and BeyondNatalie M Hendrikse, Jordi Llinares Garcia, Thorsten Vetter, et al.
Nature Reviews. Drug Discovery|April 18, 2015
Regulatory watch: Impact of scientific advice from the European Medicines AgencyMatthias P Hofer, Christina Jakobsson, Nikolaos Zafiropoulos, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Nephrology and Hypertension|July 10, 2002
Magnesium and the parathyroidThorsten Vetter, Martin J Lohse
Clinical Pharmacology and Therapeutics|February 28, 2019
Multistakeholder Advice at the European Medicines Agency: Is It Still Needed?Spiros Vamvakas, Jane Moseley, Thorsten Vetter
Therapeutic Innovation & Regulatory Science|March 4, 2023
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global AgeShannon Thor, Thorsten Vetter, Anabela Marcal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2014
GFR decline as an end point for clinical trials in CKD: a view from EuropePeter G M Mol, Romaldas Maciulaitis, Thorsten Vetter
Frontiers in Pharmacology|December 4, 2024
Identifying and overcoming challenges in the EMA's qualification of novel methodologies: a two-year reviewAna Drmić, Riccardo Saccà, Thorsten Vetter, et al.
Clinical Pharmacology and Therapeutics|January 18, 2025
Methodological Insights on Biomarker-Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines AgencyCynthia Huber, Joerg Zinserling, Norbert Benda, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 20, 2026
The use of albuminuria and proteinuria for regulatory clinical decision making: a perspective from European regulatorsFrank Holtkamp, Hrefna Gudmundsdottir, Karin Janssen van Doorn, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2019
Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European RegulatorsFrank Holtkamp, Hrefna Gudmundsdottir, Romaldas Maciulaitis, et al.
Frontiers in Medicine|May 13, 2022
Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and BeyondNatalie M Hendrikse, Jordi Llinares Garcia, Thorsten Vetter, et al.
Nature Reviews. Drug Discovery|April 18, 2015
Regulatory watch: Impact of scientific advice from the European Medicines AgencyMatthias P Hofer, Christina Jakobsson, Nikolaos Zafiropoulos, et al.
Pageof 2